Drug Trial Radar · NCT00326612
Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures
Last checked: Nov 19, 2026Latest source record: Oct 26, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
358
Actual
Start
Jun 2006
Primary completion
Dec 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- University of UtahAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Primary Children's Hospital
- First posted
- May 17, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 week, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators will conduct a randomized controlled trial comparing the use of nasal midazolam, using a Mucosal Atomization Devise, to rectal diazepam for the treatment of acute seizure activity in children under the age of 18 years with epilepsy in the community setting. The primary hypothesis is that nasal midazolam will be more effective and have shorter seizure time compared to rectal diazepam in the community. The secondary hypotheses are that patients treated with nasal midazolam will have fewer respiratory complications, emergency department visits, and admissions.
Conditions
- Seizures
Interventions
MidazolamDrug
Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.
DiazepamDrug
Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Length of Seizure After Study Medication AdministrationTime frame: 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Primary Children's Medical Center
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.